• 1. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 2. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
• 3. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 4. Excitation energies from ground-state density-functionals by means of generator coordinates
  A. B. F. da Silva,K. Capelle Phys. Chem. Chem. Phys., 2009,11, 4564-4569
• 5. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives
• Solvents and Organic Chemicals Organic Compounds Acids/Esters

Professional Introduction to Boc-N-Me-DL-Val-OH (CAS No: 13850-91-4)

Boc-N-Me-DL-Val-OH, chemically known by its CAS number 13850-91-4, is a significant compound in the field of peptidomimetics and pharmaceutical research. This compound, featuring a protected amino group and an N-methylated valine residue, has garnered considerable attention due to its utility in the synthesis of bioactive peptides and drug candidates. The structure of Boc-N-Me-DL-Val-OH incorporates a tert-butoxycarbonyl (Boc) group, which serves as an effective protecting group for the amine functionality, ensuring stability during synthetic processes.

The N-methylation at the amino position enhances the metabolic stability of the peptide analogs derived from this compound. This modification is particularly valuable in medicinal chemistry, where maintaining structural integrity under physiological conditions is crucial. The use of DL-valine provides a chiral center, allowing for the exploration of enantiomeric effects in drug design. Such features make Boc-N-Me-DL-Val-OH a versatile building block for constructing complex peptidomimetics with tailored biological activities.

In recent years, there has been a growing interest in peptidomimetics as alternative therapeutic agents due to their improved pharmacokinetic properties compared to traditional peptides. Research has demonstrated that peptidomimetics can exhibit enhanced binding affinity, reduced immunogenicity, and prolonged half-life, making them attractive candidates for drug development. The compound Boc-N-Me-DL-Val-OH has been utilized in several studies to develop novel inhibitors targeting various biological pathways.

One notable application of Boc-N-Me-DL-Val-OH is in the synthesis of protease inhibitors. Proteases play critical roles in numerous physiological processes, and their inhibition is often a key strategy in treating diseases such as cancer, inflammation, and infectious disorders. For instance, researchers have employed derivatives of Boc-N-Me-DL-Val-OH to develop inhibitors of matrix metalloproteinases (MMPs), which are involved in tissue degradation and remodeling. These inhibitors have shown promise in preclinical studies for conditions like rheumatoid arthritis and cancer metastasis.

The development of kinase inhibitors represents another significant area where Boc-N-Me-DL-Val-OH has been instrumental. Kinases are enzymes that regulate cell signaling pathways, and their dysregulation is associated with various diseases, particularly cancer. By incorporating this compound into peptidomimetic designs, scientists have created potent inhibitors targeting specific kinases. For example, studies have shown that Boc-N-Me-DL-Val-OH-based inhibitors can selectively inhibit tyrosine kinases involved in tumor growth and angiogenesis, offering potential therapeutic benefits.

Furthermore, the utility of Boc-N-Me-DL-Val-OH extends to the development of antimicrobial agents. Peptidomimetics derived from this compound have demonstrated activity against resistant bacterial strains by mimicking natural peptide antibiotics. This approach holds promise for addressing the growing problem of antibiotic resistance. Recent research has highlighted the efficacy of Boc-N-Me-DL-Val-OH-based peptidomimetics in inhibiting bacterial biofilm formation and disrupting essential bacterial processes.

The synthesis of these peptidomimetics often involves multi-step organic transformations, requiring precise control over reaction conditions to ensure high yield and purity. The Boc group provides stability during synthetic manipulations while being removable under specific acidic conditions when further functionalization is desired. The N-methyl group contributes to the overall structural stability and biological activity of the final product.

The growing body of research on peptidomimetics underscores the importance of compounds like Boc-N-Me-DL-Val-OH in drug discovery and development. Their ability to mimic natural peptides while offering improved pharmacological properties makes them valuable tools for addressing unmet medical needs. As synthetic methodologies continue to advance, it is anticipated that new derivatives of this compound will be developed, further expanding their applications in pharmaceutical research.

In conclusion, Boc-N-Me-DL-Val-OH (CAS No: 13850-91-4) is a versatile and highly valuable compound in modern medicinal chemistry. Its unique structural features make it an excellent precursor for synthesizing bioactive peptidomimetics with potential applications across various therapeutic areas. The ongoing research utilizing this compound highlights its significance and underscores its role as a cornerstone in the development of next-generation therapeutics.

• 45170-31-8((2S)-2-[[(tert-Butoxy)carbonyl](methyl)amino]-3-methylbutanoic acid)
• 52498-32-5(Boc-N-Methyl-L-isoleucine)
• 140224-14-2(N-Boc-2-(methylamino)butyric acid)
• 267223-87-0(Boc-N-methyl-D-isoleucine)
• 101759-74-4((2S)-2-{(tert-butoxy)carbonyl(methyl)amino}butanoic acid)
• 53462-50-3(Boc-N-methyl-D-allo-isoleucine)
• 35761-42-3(Boc-N-methyl-L-valine dicyclohexylammonium salt)
• 24164-06-5(NSC 135130)
• 136092-80-3(Boc-N-Me-Allo-Ile-OH)
• 89536-85-6((R)-2-((tert-Butoxycarbonyl)(methyl)amino)-3-methylbutanoic acid)